CSF Biomarkers for Alzheimer's Disease: Levels of beta-Amyloid, Tau, Phosphorylated Tau Relate to Clinical Symptoms and Survival.
(2006) In Dementia and Geriatric Cognitive Disorders 21(3). p.131-138- Abstract
- Cerebrospinal fluid (CSF) samples from 21 patients with a clinical diagnosis of Alzheimer's disease (AD) participating in a 5-year treatment study with the choline esterase inhibitor tacrin were retrospectively analyzed for the contents of beta-amyloid (Abeta42), total tau (T-tau) and phosphorylated tau (P-tau). A significant positive correlation between the level of P-tau and the number of symptoms according to the DSM-IV criteria (p = 0.041) and the NINCDS-ADRDA (p = 0.029) was observed (i.e. higher levels were found in cases with more symptoms). A significant positive correlation between T-tau, P-tau and ADAS-cog score was identified (i.e. higher levels were found with more severe cognitive dysfunction). Patients who died during the... (More)
- Cerebrospinal fluid (CSF) samples from 21 patients with a clinical diagnosis of Alzheimer's disease (AD) participating in a 5-year treatment study with the choline esterase inhibitor tacrin were retrospectively analyzed for the contents of beta-amyloid (Abeta42), total tau (T-tau) and phosphorylated tau (P-tau). A significant positive correlation between the level of P-tau and the number of symptoms according to the DSM-IV criteria (p = 0.041) and the NINCDS-ADRDA (p = 0.029) was observed (i.e. higher levels were found in cases with more symptoms). A significant positive correlation between T-tau, P-tau and ADAS-cog score was identified (i.e. higher levels were found with more severe cognitive dysfunction). Patients who died during the 5-year follow-up had significantly lower levels of Abeta42 (p = 0.011) than those who were still alive. Patients who had died in a 6-year follow-up had significantly lower levels of Abeta42 (p = 0.034) and higher levels of T-tau (p = 0.041) than patients still alive. Conclusion: CSF biomarkers do aid the clinical diagnosis of AD. Increased levels of P-tau and T-tau are possible markers for severity and abundance of symptoms in AD. Low levels of Abeta42 may indicate a higher risk of early death in AD. (Less)
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/150544
- author
- Wallin, Åsa LU ; Blennow, K ; Andreasen, N and Minthon, Lennart LU
- organization
- publishing date
- 2006
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- tau, phosphorylated tau, tacrine, survival, Apo E, beta-amyloid, Alzheimer's disease, cerebrospinal fluid
- in
- Dementia and Geriatric Cognitive Disorders
- volume
- 21
- issue
- 3
- pages
- 131 - 138
- publisher
- Karger
- external identifiers
-
- pmid:16391474
- wos:000234829000001
- scopus:32044436030
- pmid:16391474
- ISSN
- 1420-8008
- DOI
- 10.1159/000090631
- language
- English
- LU publication?
- yes
- id
- 231d5fb6-05cf-444e-8faf-89a9bec8e139 (old id 150544)
- date added to LUP
- 2016-04-01 11:40:47
- date last changed
- 2022-02-10 19:57:36
@article{231d5fb6-05cf-444e-8faf-89a9bec8e139, abstract = {{Cerebrospinal fluid (CSF) samples from 21 patients with a clinical diagnosis of Alzheimer's disease (AD) participating in a 5-year treatment study with the choline esterase inhibitor tacrin were retrospectively analyzed for the contents of beta-amyloid (Abeta42), total tau (T-tau) and phosphorylated tau (P-tau). A significant positive correlation between the level of P-tau and the number of symptoms according to the DSM-IV criteria (p = 0.041) and the NINCDS-ADRDA (p = 0.029) was observed (i.e. higher levels were found in cases with more symptoms). A significant positive correlation between T-tau, P-tau and ADAS-cog score was identified (i.e. higher levels were found with more severe cognitive dysfunction). Patients who died during the 5-year follow-up had significantly lower levels of Abeta42 (p = 0.011) than those who were still alive. Patients who had died in a 6-year follow-up had significantly lower levels of Abeta42 (p = 0.034) and higher levels of T-tau (p = 0.041) than patients still alive. Conclusion: CSF biomarkers do aid the clinical diagnosis of AD. Increased levels of P-tau and T-tau are possible markers for severity and abundance of symptoms in AD. Low levels of Abeta42 may indicate a higher risk of early death in AD.}}, author = {{Wallin, Åsa and Blennow, K and Andreasen, N and Minthon, Lennart}}, issn = {{1420-8008}}, keywords = {{tau; phosphorylated tau; tacrine; survival; Apo E; beta-amyloid; Alzheimer's disease; cerebrospinal fluid}}, language = {{eng}}, number = {{3}}, pages = {{131--138}}, publisher = {{Karger}}, series = {{Dementia and Geriatric Cognitive Disorders}}, title = {{CSF Biomarkers for Alzheimer's Disease: Levels of beta-Amyloid, Tau, Phosphorylated Tau Relate to Clinical Symptoms and Survival.}}, url = {{http://dx.doi.org/10.1159/000090631}}, doi = {{10.1159/000090631}}, volume = {{21}}, year = {{2006}}, }